Sex: M
Vaccine: COVID19
Symptoms: Bronchitis, Diabetes mellitus, Pulmonary hypertension, Pulmonary thrombosis
Clinical narrative: diabetes; CTEPH; Bronchitis; blood clots in lungs; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP).  An 81-year-old male patient received BNT162b2 (BNT162B2), on 13Feb2021 as dose 2, single (Lot number: EL1283) intramuscular, in left arm for covid-19 immunisation. The patient's relevant medical history included: "HHT- Hereditary Hemorrhagic telangiectasia", start date: 1963 (ongoing), notes: Numerous electrocautery sometimes under sedatio most recent was 28Nov2022; "blocked arteries", start date: 2010 (unspecified if ongoing), notes: bannot take blood thinners due to HHT, Pertinent Details: Quad by pass 2010  for blocked arteries; "Cholesterol" (unspecified if ongoing); "Thyroid" (unspecified if ongoing); "Heart" (unspecified if ongoing); "Nose" (unspecified if ongoing). Concomitant medication(s) included: SIMVASTATIN taken for blood cholesterol (ongoing); LEVOTHYROXINE taken for thyroid disorder (ongoing); BACTROBAN [MUPIROCIN] taken for nasal injury (ongoing); BETAPACE taken for cardiac disorder (ongoing). Vaccination history included: BNT162b2 (DOSE 1, SINGLE, Time (24hr): 2-3 PM, Anatomical site of injection: upper left arm, Route of administration: Intramuscular , Batch/Lot number: EL1283), administration date: 22Jan2021, for COVID-19 immunization, reaction(s): "congested", "wheezing". The following information was reported: BRONCHITIS (disability, life threatening) with onset Feb2021, outcome "not recovered"; PULMONARY HYPERTENSION (disability, life threatening) with onset Feb2021, outcome "not recovered", described as "CTEPH"; DIABETES MELLITUS (disability, medically significant) with onset May2021, outcome "not recovered", described as "diabetes"; PULMONARY THROMBOSIS (disability, medically significant) with onset 2021, outcome "not recovered", described as "blood clots in lungs". The events "cteph" and "bronchitis" required physician office visit. Therapeutic measures were taken as a result of pulmonary hypertension, bronchitis and the patient received riociguat (ADEMPAS) 3x/day 2.5 mg. The patient had bronchitis in Feb2021. Treated numerous times with antibiotic in May2022 diagnosed with blood clots in lungs (which we were told actually slower up in Jul2021).The reporter and patient were not informed in 21Jul2022, they went to (withheld) in (withheld). New diagnosed with CTEPH (Chromic Thromboembolic Pulmonary Hypertension). The reporter and the patient received the first vaccine on 22Jan2021. The reporter had no problems whatsoever. The patient started wheezing and being congested, they did not suspect it could related to vaccine, they thought the patient had bronchitis and the Dr treated it as such, with antibiotics. He would get better and then it would start all over again. The reporter thought it was in May2021. The patient was diagnosed with diabetes. The breathing problems continued. The patient was put on riociguat and was at the full dose.; Sender's Comments: Linked Report(s) : US-PFIZER INC-PV202300020963 same patient/product, different event and dose;